Related Experiment Video
Updated: Jun 4, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous
Azhi ShaMa1, Chunlan Ma1, Yingying Huang1
1Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University), Chongqing, People's Republic of China.
Insights
Elevated lipoprotein(a) (Lp[a]) does not increase the risk of in-stent restenosis or repeat procedures in patients with coronary artery disease after percutaneous coronary intervention. This finding is crucial for understanding Lp(a) in secondary prevention.
Area of Science:
- Cardiology
- Clinical Research
- Lipid Metabolism
Background:
- Elevated lipoprotein(a) (Lp[a]) is a known risk factor for initial atherosclerotic events.
- Its role in secondary prevention of cardiovascular disease remains controversial.
- This study investigates Lp(a) in patients with established coronary artery disease.
Purpose of the Study:
- To retrospectively analyze the impact of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.
- To evaluate the association between Lp(a) and outcomes following percutaneous coronary intervention (PCI).
Main Methods:
- Retrospective analysis of clinical data from patients hospitalized during PCI.
- Multivariate logistic regression was used to assess relationships between Lp(a), risk factors, and prognosis.
- Outcomes were assessed one year post-PCI via coronary angiography.
Main Results:
- No significant differences were observed in baseline characteristics or cardiovascular risk factors between Lp(a) groups.
- Lp(a) levels did not significantly decrease after one year of statin treatment.
- High Lp(a) levels did not significantly increase the incidence of in-stent restenosis or secondary PCI one year after PCI.
Conclusions:
- Sustained high lipoprotein(a) levels do not appear to significantly elevate the risk of in-stent restenosis or the need for secondary PCI in patients with coronary artery disease.
- These findings suggest Lp(a) may not be a significant predictor of adverse outcomes in secondary cardiovascular prevention after PCI.
Background:
Elevated lipoprotein(a) (Lp[a]) is a risk factor for first atherosclerotic thrombosis events, but the role of elevated Lp(a) in secondary prevention is controversial. This study aimed to retrospectively investigate the influence of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.
Methods:
The team collected and compared clinical information of patients hospitalized during percutaneous coronary intervention (PCI). This study used a multivariate logistic regression model to evaluate the relationships between Lp(a) levels, cardiovascular risk factors, and the prognosis of coronary artery disease in patients undergoing PCI.
Results:
There were no statistically significant differences between patients grouped according to Lp(a) level in terms of sex; age; body mass index and obesity; hyperuricemia; smoking; cardiac insufficiency; acute myocardial infarction; multivessel lesion; in-stent restenosis; secondary PCI; apolipoprotein AI level; incidence of high total cholesterol or high low-density lipoprotein cholesterol; or family history of hypertension, diabetes, or coronary artery disease. The average Lp(a) concentration did not statistically significantly decrease after 1 year of statin treatment after PCI. One year after patients began statins, there were no significant differences between Lp(a) groups in the incidence of high triglycerides (P = .13), high total cholesterol (P = .52), or high low-density lipoprotein cholesterol (P = .051). Multivariate logistic regression analysis indicated that diabetes (P = .02) was associated with in-stent restenosis, whereas diabetes (P = .02) and multivessel lesions (P < .001) were associated with secondary PCI in patients who underwent coronary angiography 1 year after PCI. Compared with normal Lp(a) levels, high Lp(a) levels did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.
Conclusion:
Sustained high concentrations of Lp(a) did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT